Entera Bio Ltd (DE:5DT)
FRANKFURT:5DT
5DT Stock Chart & Stats
€0.97
-€0.06(-2.36%)
At close: 4:00 PM EST
€0.97
-€0.06(-2.36%)
Day’s Range― - ―
52-Week Range€0.84 - €2.66
Previous CloseN/A
Volume0.00
Average Volume (3M)77.00
Market Cap
€70.52M
Enterprise Value€55.46M
Total Cash (Recent Filing)€4.14M
Total Debt (Recent Filing)€448.00K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Aug 07, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding49,290,234
10 Day Avg. Volume104
30 Day Avg. Volume77
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)6.84
Price to Sales (P/S)2133.59
P/FCF Ratio-11.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.91Price Target Upside715.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.36
Revenue Forecast (FY)€46.41M
Bulls Say, Bears Say
Bulls Say
Regulatory Alignment For Phase 3Clear FDA feedback and acceptance of a single, randomized, placebo‑controlled Phase 3 protocol materially reduces pivotal regulatory uncertainty. This durable alignment clarifies endpoints, supports a 505 bridge to Forteo, and strengthens the path to an NDA—lowering long‑term approval risk and improving partner/financing prospects.
Platform Versatility Across IndicationsPreclinical and conference data demonstrating consistent oral peptide bioavailability across bone, hypoparathyroidism and metabolic targets indicate a platform advantage versus injectables. A broadly applicable delivery technology creates durable optionality, potential multiple product franchises, and stronger partnership/leverage opportunities over time.
Low Leverage And Improved Near-term LiquidityA very low debt load combined with a recent $10M financing that increased cash balances materially reduces short‑term insolvency risk and preserves operational flexibility. This stronger liquidity profile supports late‑stage planning for EB613 and protects runway into the coming quarters while limiting near‑term refinancing stress.
Bears Say
No Commercial Revenue And Persistent LossesAs a pre‑commercial biotech, Entera has no product revenue and sustained operating losses. That structural absence of recurring revenue means long‑term viability depends on clinical success or continued external funding; repeated losses dilute equity and limit self‑funding capacity over months to years.
Deteriorating Cash Generation And High BurnSteep negative operating and free cash flow reflect cash‑based losses and rising R&D spend. This durable cash burn increases dependency on capital markets or partners, heightening execution risk for multi‑year trials and creating a structural funding overhang that can force dilutive financing before commercialization.
Long Timeline To Potential CommercializationA multi‑year development timetable means material value realization is distant and contingent on trial outcomes, safety and regulatory review. Extended timelines amplify exposure to clinical, regulatory and funding risks, and compress time for revenue generation—structural constraints for near‑term sustainability.
Entera Bio News
5DT FAQ
What was Entera Bio Ltd’s price range in the past 12 months?
Entera Bio Ltd lowest stock price was €0.84 and its highest was €2.66 in the past 12 months.
What is Entera Bio Ltd’s market cap?
Entera Bio Ltd’s market cap is €70.52M.
When is Entera Bio Ltd’s upcoming earnings report date?
Entera Bio Ltd’s upcoming earnings report date is Aug 07, 2026 which is in 40 days.
How were Entera Bio Ltd’s earnings last quarter?
Entera Bio Ltd released its earnings results on May 08, 2026. The company reported -€0.06 earnings per share for the quarter, beating the consensus estimate of -€0.069 by €0.009.
Is Entera Bio Ltd overvalued?
According to Wall Street analysts Entera Bio Ltd’s price is currently Undervalued.
Does Entera Bio Ltd pay dividends?
Entera Bio Ltd does not currently pay dividends.
What is Entera Bio Ltd’s EPS estimate?
Entera Bio Ltd’s EPS estimate is -0.07.
How many shares outstanding does Entera Bio Ltd have?
Entera Bio Ltd has 49,290,234 shares outstanding.
What happened to Entera Bio Ltd’s price movement after its last earnings report?
Entera Bio Ltd reported an EPS of -€0.06 in its last earnings report, beating expectations of -€0.069. Following the earnings report the stock price went down -5.31%.
Which hedge fund is a major shareholder of Entera Bio Ltd?
Currently, no hedge funds are holding shares in DE:5DT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Entera Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.91 (715.61% Upside)
€7.91 (715.61% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.37%
12-Months-Change
Fundamentals
Return on Equity
-87.97%
Trailing 12-Months
Asset Growth
-39.22%
Trailing 12-Months
Company Description
Entera Bio Ltd
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
5DT Stock 12 Month Forecast
Average Price Target
€7.91
▲(715.61% Upside)
Technical Analysis
Options Prices
Currently, No data available
---